Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Amycretin

Investigational

Dual GLP-1 and amylin agonist

Evidence score

43/ 100

Emerging evidence

Early evidence, mostly unproven in humans

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 1 registered study on ClinicalTrials.gov, most advanced Phase 1
No sources. Nothing cited to verify

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Amycretin is an investigational peptide developed by Novo Nordisk that is designed to activate both the GLP-1 receptor and the amylin receptor in a single molecule. Both pathways are involved in appetite, fullness, and blood sugar regulation, and the compound is being studied mainly for weight management.

What the evidence shows

Automatic summaryLimited human data

Early human studies, with one registered trial listed at Phase 1 in the provided data, have reported effects on body weight and tolerability in small groups, but these results are preliminary. Long-term safety and effectiveness have not been established, and it is not FDA-approved for any use.

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

1registered studies

Phase 1most advanced phase

1completed (sample)

0recruiting (sample)

A Research Study of How a New Medicine Called Amycretin, Given as Tablets, Works in Japanese Men With Obesity

Phase 1CompletedNCT06049329

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

22papers referencing Amycretin

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.

Lancet2025

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.

Lancet2025

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Peptides2025

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.

EBioMedicine2025

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.